Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,494 active trials253 approved drugs3,567 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,594 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04130854 | INNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer | completed | Phase 2 | 58 | University of Texas Southwestern Medical CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04268134 | Altering Lipids for Tolerance of Aromatase Inhibitor Therapy(ALTA) | completed | Phase 2 | 77 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 6, 2026 |
| NCT05532722 | ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL) | completed | Phase 1 / Phase 2 | 21 | Abcuro, Inc.INDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT07568444 | Enhancing Readability of Lay Abstracts and Summaries for Medical Knowledge Using Generative Artificial Intelligence (BRIDGE AI 3) | completed | Phase 2 | 120 | University of Southern CaliforniaOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT01670500 | Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa | completed | Phase 2 | 118 | Beth Israel Deaconess Medical CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT03477539 | Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma | completed | Phase 2 | 49 | Mayo ClinicOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT03580564 | An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma | completed | Phase 2 | 109 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT03848286 | KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal Carcinoma | completed | Phase 2 | 153 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT04665843 | A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck(SKYSCRAPER-09) | completed | Phase 2 | 123 | Hoffmann-La RocheINDUSTRY | 13 | May 5, 2026 | clinicaltrials |
| NCT04807816 | Targeting ATR in Soft-tissue Sarcomas(TARSARC) | completed | Phase 2 | 58 | Institut BergoniéOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05005728 | XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 72 | Xencor, Inc.INDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT05064358 | Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma(DREAMM 14) | completed | Phase 2 | 177 | GlaxoSmithKlineINDUSTRY | 18 | May 5, 2026 | clinicaltrials |
| NCT02314481 | Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity(DARWINII) | completed | Phase 2 | 50 | University College, LondonOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT03035331 | Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 11 | Mayo ClinicOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT03563716 | A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | completed | Phase 2 | 135 | Genentech, Inc.INDUSTRY | 6 | May 4, 2026 | clinicaltrials |
| NCT03797326 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | completed | Phase 2 | 611 | Merck Sharp & Dohme LLCINDUSTRY | 17 | May 4, 2026 | clinicaltrials |
| NCT04083534 | First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM) | completed | Phase 1 / Phase 2 | 43 | Regeneron PharmaceuticalsINDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT05865990 | HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease(TUXEDO-3) | completed | Phase 2 | 63 | MedSIROTHER | 2 | May 4, 2026 | clinicaltrials |
| NCT06608238 | Phase 2 Study Evaluating the Safety and Efficacy of Microneedle-mediated Delivery of Doxorubicin (D-MNA) in Patients With Nodular Basal Cell Carcinoma. | completed | Phase 2 | 90 | SkinJect, Inc.INDUSTRY | 2 | May 4, 2026 | clinicaltrials |
| NCT04118114 | Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors | completed | Phase 2 | 14 | National Cancer Centre, SingaporeOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT01625234 | Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 131 | Xcovery Holdings, Inc.INDUSTRY | 1 | Apr 30, 2026 | clinicaltrials |
| NCT02700386 | Shorter Course Radiation for the Treatment of Breast Cancer That Has Spread to Lymph Nodes | completed | Phase 2 | 108 | University of Colorado, DenverOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT03802071 | A Study of Durvalumab in Combination With Doxorubicin for Advanced Soft Tissue Sarcoma | completed | Phase 1 / Phase 2 | 44 | Yonsei UniversityOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT05004350 | A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.(NAUTICALCRC) | completed | Phase 2 | 107 | Pierre Fabre MedicamentINDUSTRY | 1 | Apr 30, 2026 | clinicaltrials |
| NCT05613088 | A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 106 | Bristol-Myers SquibbINDUSTRY | 9 | Apr 30, 2026 | clinicaltrials |
| NCT07024537 | FOLFOXIRI-based HAIC Combined With Fuquintinib as Late-line Treatment in Patients With CRLM：A Phase 2 Single-Arm Clinical Trial(HAIC，CRLM) | completed | Phase 2 | 44 | Meng QiuOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT00558519 | Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | completed | Phase 2 | 318 | Alliance for Clinical Trials in OncologyOTHER | 0 | Apr 29, 2026 | clinicaltrials |
| NCT02649855 | Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer | completed | Phase 2 | 74 | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2026 | clinicaltrials |
| NCT03902184 | IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma(TELLOMAK) | completed | Phase 2 | 170 | Innate PharmaINDUSTRY | 8 | Apr 29, 2026 | clinicaltrials |
| NCT00253435 | N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma | completed | Phase 2 | 50 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 2 | Apr 28, 2026 | clinicaltrials |
| NCT01744249 | Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas | completed | Phase 2 / Phase 3 | 256 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 4 | Apr 28, 2026 | clinicaltrials |
| NCT02664935 | National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer | completed | Phase 2 | 423 | University of BirminghamOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT02839265 | FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer(FLT3) | completed | Phase 2 | 33 | Montefiore Medical CenterOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT05014776 | Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer | completed | Phase 2 | 17 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT05133440 | A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones | completed | Phase 2 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT05156268 | A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma | completed | Phase 2 | 26 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06428487 | Neoadjuvant Prolgolimab Monotherapy in Locally Advanced MMR-deficient Colorectal Cancer | completed | Phase 2 | 30 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT03068819 | Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant | completed | Phase 1 / Phase 2 | 62 | Washington University School of MedicineOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT03580655 | (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis | completed | Phase 2 | 107 | Blueprint Medicines CorporationINDUSTRY | 12 | Apr 24, 2026 | clinicaltrials |
| NCT03818061 | Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck(ATHENA) | completed | Phase 2 | 33 | Centre Leon BerardOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT05213884 | The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC | completed | Phase 2 | 39 | Chongqing University Cancer HospitalOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT05388123 | Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia | completed | Phase 2 | 15 | Scripps HealthOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT06059014 | Phase I/II Study Evaluating PSMA Targeted Radionuclide Therapy in Adult Patients With Metastatic Clear Cell Renal Cancer(PRadR) | completed | Phase 1 / Phase 2 | 6 | Centre Leon BerardOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT02316106 | A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma | completed | Phase 2 | 123 | Janssen Research & Development, LLCINDUSTRY | 11 | Apr 23, 2026 | clinicaltrials |
| NCT02661542 | Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas | completed | Phase 1 / Phase 2 | 106 | Fujifilm Pharmaceuticals U.S.A., Inc.INDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT04216953 | MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma(COTESARC) | completed | Phase 1 / Phase 2 | 229 | Centre Leon BerardOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT04925648 | Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction(PICASSO) | completed | Phase 2 | 4 | St Vincent's Hospital, SydneyOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05187884 | Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma(NADOM) | completed | Phase 2 | 15 | St Vincent's Hospital, SydneyOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05625893 | Proton Beam Radiotherapy Followed by Tecentriq and Avastin for Primary Liver Cancer With Vp2-4 Portal Vein Invasion | completed | Phase 2 | 63 | Samsung Medical CenterOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT02433795 | Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL) | completed | Phase 2 | 27 | Seoul National University HospitalOTHER | 1 | Apr 22, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 6, 2026source: clinicaltrials